Adrenergic Hyperactivity
Links shared publicly online about this topic
The Rationale for Selective 2A Adrenergic Agonists in the Treatment of Attention-deficit"Hyperactivity Disorder | Neurology
touchneurology.com — “The Rationale for Selective 2A Adrenergic Agonists in the Treatment of Attention-deficit"Hyperactivity Disorder” View full resource at touchneurology.com
Most Recently Shared on November 12, 2009 at 1:00 pm By:
touchNEURO Health Site and Neurology
Treatment of Attention-deficit–Hyperactivity Disorder http://ow.ly/z8Fw
Shire Announces FDA Approval of Once-Daily Intuniv (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
drugs.com — “Intuniv (guanfacine) is used to treat Attention-Deficit/Hyperactivity Disorder in children and adolescents aged 6 to 17 years. Includes Intuniv side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on September 4, 2009 at 12:32 am By:
FDA Approves Intuniv (guanfacine) for the Treatment of ADHD in Children and Adolescents - http://bit.ly/EObbC
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
touchNEURO
Touch NEUROLOGY enables time-pressured physicians to stay abreast of key advances in the neurological industry. Including info on disorders, symptoms & diseases
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
Advertisement
